Tag: active surveillance

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

Gleason 3+3 prostate cancer is often considered low-risk—so low that some experts say it shouldn’t even be called cancer at all. But could a new label change how patients view their diagnosis and choices? The answer may reshape the future of prostate cancer care. keep reading

Gleason 6 prostate cancer has long sparked debate: is it really “cancer” if it rarely spreads? While many experts argue it’s essentially harmless, new research suggests that certain biopsy findings may predict higher risk. Here’s what men on Active Surveillance need to know. keep reading

Active Surveillance helps men with low-risk prostate cancer avoid overtreatment, but anxiety and repeated biopsies can take a toll. A new approach—Super Active Surveillance—combines MRI monitoring with focal therapy, offering peace of mind while keeping future treatment options open. keep reading

What’s harder—treating prostate cancer, or living with the knowledge it’s still inside you? Research shows Active Surveillance may lead to significant anxiety and depression for some patients, raising important questions about how to balance safety, treatment, and peace of mind. keep reading

Overtreatment of low-risk prostate cancer can leave men with lasting side effects from unnecessary whole-gland treatment. Today, advances like multiparametric MRI, active surveillance, and focal therapy are offering safer, smarter alternatives that protect health and preserve quality of life. keep reading

How times and technology change! Take, for example, the shift from a tangible book like the Yellow Pages to a digital one. At one time, paper copies of the Yellow Pages business directory were delivered to virtually every household in America. This hefty local book was the ultimate resource for finding a business or service keep reading

“What treatment do most patients choose?” Occasionally I’m asked this question, so I thought it would be interesting to present some statistics from published studies. 2011 data (low risk PCa) I’ll start with data presented in a 2011 article by a British team.[i] The authors collected records on 768 of their center’s patients with early keep reading

Okay, folks, this is BIG NEWS! A research study out of the esteemed Johns Hopkins University School of Medicine and two other academic centers may be the first of its kind to definitively connect healthy diet with reining in prostate cancer (PCa). Specifically, the study population was done with PCa patients currently on Active Surveillance keep reading

The strategy of using active surveillance (AS) is increasingly recommended to low-risk prostate cancer (PCa) patients as a way to avoid or delay overtreatment. This is a new way of thinking; before the New Millennium, PCa was assumed to be multi-focal and most men with more than 10 years of life expectancy were hurried into surgery or radiation. Today’s terminology includes words that might have been meaningless a decade ago, e.g. indolent cancer, very low risk disease, and focal disease are all consistent with the growing movement toward AS. keep reading